Patents by Inventor Lali K. Medina-Kauwe
Lali K. Medina-Kauwe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11795454Abstract: The present invention relates a targeted delivery system for siRNA or antisense technology. In one embodiment, the invention provides for a method of treating cancer by administering a therapeutically effective dosage of HerPBK10 combined with siRNA, resulting in the inhibition of Her2 expression and cell death. In another embodiment, a plurality of HerPBK10 combined with siRNA form a nanoparticle.Type: GrantFiled: June 10, 2020Date of Patent: October 24, 2023Assignee: CEDARS-SINAI MEDICAL CENTERInventor: Lali K. Medina-Kauwe
-
Publication number: 20220362389Abstract: Disclosed herein are drug delivery molecules that comprise a ligand that targets a cell surface molecule; a membrane penetration domain; and a payload binding domain; and pharmaceutical compositions comprising the same. Also disclosed are methods of treating cancer, inhibiting the progression of cancer, preventing cancer metastasis, and delivering a therapeutic compound to the brain in a subject in need thereof, the methods comprising identifying a subject in need thereof; providing a composition comprising the drug delivery molecule as disclosed herein; and administering an effective amount of the composition to the subject.Type: ApplicationFiled: May 23, 2022Publication date: November 17, 2022Inventor: Lali K. MEDINA-KAUWE
-
Patent number: 11369687Abstract: Disclosed herein are drug delivery molecules that comprise a ligand that targets a cell surface molecule; a membrane penetration domain; and a payload binding domain; and pharmaceutical compositions comprising the same. Also disclosed are methods of treating cancer, inhibiting the progression of cancer, preventing cancer metastasis, and delivering a therapeutic compound to the brain in a subject in need thereof, the methods comprising identifying a subject in need thereof; providing a composition comprising the drug delivery molecule as disclosed herein; and administering an effective amount of the composition to the subject.Type: GrantFiled: November 20, 2018Date of Patent: June 28, 2022Assignee: CEDARS-SINAI MEDICAL CENTERInventor: Lali K. Medina-Kauwe
-
Publication number: 20210147835Abstract: The present invention relates a targeted delivery system for siRNA or antisense technology. In one embodiment, the invention provides for a method of treating cancer by administering a therapeutically effective dosage of HerPBK10 combined with siRNA, resulting in the inhibition of Her2 expression and cell death. In another embodiment, a plurality of HerPBK10 combined with siRNA form a nanoparticle.Type: ApplicationFiled: June 10, 2020Publication date: May 20, 2021Inventor: Lali K. MEDINA-KAUWE
-
Publication number: 20210077575Abstract: Nanoparticles can be useful for delivering therapeutic agents, such as anticancer agents to diseased cells. The nanoparticles include a carrier polypeptide and a cargo, which can be bind through electrostatic interactions to form a nanoparticle composition. An exemplary composition comprises nanoparticles comprising a carrier polypeptide comprising a penton base segment and a binding segment: and a polypeptide cargo comprising a tag segment that binds to the binding segment of the carrier poly peptide through an electrostatic interaction. An exemplary carrier polypeptide comprises a person base segment and a negatively-charged binding segment, which can bind to a positively charged cargo. The carrier polypeptide can also include a cell-targeting segment which can target the nanoparticle to a cell. Compositions comprising nanoparticles can be administered to a subject for the treatment of disease, such as cancer.Type: ApplicationFiled: December 28, 2018Publication date: March 18, 2021Inventor: Lali K. MEDINA-KAUWE
-
Patent number: 10793853Abstract: The present invention relates a targeted delivery system for siRNA or antisense technology. In one embodiment, the invention provides for a method of treating cancer by administering a therapeutically effective dosage of HerPBK10 combined with siRNA, resulting in the inhibition of Her2 expression and cell death. In another embodiment, a plurality of HerPBK10 combined with siRNA form a nanoparticle.Type: GrantFiled: July 22, 2011Date of Patent: October 6, 2020Assignee: CEDARS-SINAI MEDICAL CENTERInventor: Lali K. Medina-Kauwe
-
Patent number: 10752893Abstract: The invention relates to methods for isolating traffic-enhancing mutants of drug delivery proteins. In one embodiment, the invention provides a carrier for delivering a therapeutic agent to an organelle, comprising a polypeptide encoded by a mutant penton base gene. In another embodiment, the invention provides a method of enhancing trafficking to a cell by administering a composition comprising a penton base (PB) protein with one or more mutations that enhance cellular entry.Type: GrantFiled: June 25, 2018Date of Patent: August 25, 2020Assignee: CEDARS-SINAI MEDICAL CENTERInventor: Lali K. Medina-Kauwe
-
Patent number: 10709801Abstract: Disclosed herein are compositions comprising a targeted corrole nanoparticle; and an acceptable excipient. Also disclosed are compositions comprising a targeted corrole nanoparticle; and an acceptable carrier. Further, disclosed herein are methods of imaging a condition in a subject, comprising providing a composition comprising a targeted corrole nanoparticle; administering an effective amount of the targeted corrole nanoparticle to the subject; and imaging the condition in the subject. In addition, disclosed herein are methods of treating cancer in a subject, comprising providing a composition comprising a targeted corrole nanoparticle; and administering a therapeutically effective dosage of the targeted corrole nanoparticle to the subject.Type: GrantFiled: June 15, 2017Date of Patent: July 14, 2020Assignee: CEDARS-SINAI MEDICAL CENTERInventor: Lali K. Medina-Kauwe
-
Patent number: 10391180Abstract: The present invention relates to a complex that can be injected into the body to hone in on target cells to deliver molecules. In one embodiment, the invention provides a drug delivery system that includes components that self-assemble into one targeted conjugate. In another embodiment, the invention includes a targeted carrier protein and a nucleic acid sequence non-covalently linked to one or more drugs.Type: GrantFiled: September 13, 2017Date of Patent: August 27, 2019Assignee: CEDARS-SINAI MEDICAL CENTERInventor: Lali K. Medina-Kauwe
-
Publication number: 20190175747Abstract: Disclosed herein are compositions comprising nanoparticles comprising a carrier polypeptide and a double-stranded oligonucleotide, wherein the carrier polypeptide comprises a cell-targeting segment, a cell-penetrating segment, and an oligonucleotide-binding segment: and wherein the molar ratio of the carrier polypeptide to the double-stranded oligonucleotide in the nanoparticle composition is less than about 6:1, along with methods of making and using such nanoparticles. Further described are methods of treating a subject with a cancer, such as a chemotherapeutic drug resistant cancer comprising administering to the subject a composition comprising nanoparticles, the nanoparticles comprising a carrier polypeptide comprising a cell-targeting segment, a cell-penetrating segment, and an oligonucleotide-binding segment; a double-stranded oligonucleotide bound to the oligonucleotide-binding segment; and a chemotherapeutic drug bound to the double-stranded oligonucleotide.Type: ApplicationFiled: May 26, 2017Publication date: June 13, 2019Inventor: Lali K. MEDINA-KAUWE
-
Publication number: 20190142962Abstract: Disclosed herein are drug delivery molecules that comprise a ligand that targets a cell surface molecule; a membrane penetration domain; and a payload binding domain; and pharmaceutical compositions comprising the same. Also disclosed are methods of treating cancer, inhibiting the progression of cancer, preventing cancer metastasis, and delivering a therapeutic compound to the brain in a subject in need thereof, the methods comprising identifying a subject in need thereof; providing a composition comprising the drug delivery molecule as disclosed herein; and administering an effective amount of the composition to the subject.Type: ApplicationFiled: November 20, 2018Publication date: May 16, 2019Inventor: Lali K. MEDINA-KAUWE
-
Patent number: 10183078Abstract: Disclosed herein are drug delivery molecules that comprise a ligand that targets a cell surface molecule; a membrane penetration domain; and a payload binding domain; and pharmaceutical compositions comprising the same. Also disclosed are methods of treating cancer, inhibiting the progression of cancer, preventing cancer metastasis, and delivering a therapeutic compound to the brain in a subject in need thereof, the methods comprising identifying a subject in need thereof; providing a composition comprising the drug delivery molecule as disclosed herein; and administering an effective amount of the composition to the subject.Type: GrantFiled: January 16, 2015Date of Patent: January 22, 2019Assignee: CEDARS-SINAI MEDICAL CENTERInventor: Lali K. Medina-Kauwe
-
Publication number: 20180298376Abstract: The invention relates to methods for isolating traffic-enhancing mutants of drug delivery proteins. In one embodiment, the invention provides a carrier for delivering a therapeutic agent to an organelle, comprising a polypeptide encoded by a mutant penton base gene. In another embodiment, the invention provides a method of enhancing trafficking to a cell by administering a composition comprising a penton base (PB) protein with one or more mutations that enhance cellular entry.Type: ApplicationFiled: June 25, 2018Publication date: October 18, 2018Inventor: Lali K. Medina-Kauwe
-
Patent number: 10036009Abstract: The invention relates to methods for isolating traffic-enhancing mutants of drug delivery proteins. In one embodiment, the invention provides a carrier for delivering a therapeutic agent to an organelle, comprising a polypeptide encoded by a mutant penton base gene. In another embodiment, the invention provides a method of enhancing trafficking to a cell by administering a composition comprising a penton base (PB) protein with one or more mutations that enhance cellular entry.Type: GrantFiled: August 2, 2013Date of Patent: July 31, 2018Assignee: CEDARS-SINAI MEDICAL CENTERInventor: Lali K. Medina-Kauwe
-
Publication number: 20180066033Abstract: Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.Type: ApplicationFiled: November 17, 2017Publication date: March 8, 2018Inventors: Lali K. MEDINA-KAUWE, Jessica SIMS, Michael TAGUAIM, Chris HANSON, Xiaojiang CUI
-
Publication number: 20180028678Abstract: The present invention relates to a complex that can be injected into the body to hone in on target cells to deliver molecules. In one embodiment, the invention provides a drug delivery system that includes components that self-assemble into one targeted conjugate. In another embodiment, the invention includes a targeted carrier protein and a nucleic acid sequence non-covalently linked to one or more drugs.Type: ApplicationFiled: September 13, 2017Publication date: February 1, 2018Inventor: Lali K. MEDINA-KAUWE
-
Patent number: 9850293Abstract: Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.Type: GrantFiled: April 4, 2015Date of Patent: December 26, 2017Assignee: CEDARS-SINAI MEDICAL CENTERInventors: Lali K. Medina-Kauwe, Jessica Sims, Michael Taguaim, Chris Hanson, Xiaojiang Cui
-
Patent number: 9789201Abstract: The present invention relates to a complex that can be injected into the body to hone in on target cells to deliver molecules. In one embodiment, the invention provides a drug delivery system that includes components that self-assemble into one targeted conjugate. In another embodiment, the invention includes a targeted carrier protein and a nucleic acid sequence non-covalently linked to one or more drugs.Type: GrantFiled: July 10, 2015Date of Patent: October 17, 2017Assignee: CEDARS-SINAI MEDICAL CENTERInventor: Lali K. Medina-Kauwe
-
Publication number: 20170281802Abstract: Disclosed herein are compositions comprising a targeted corrole nanoparticle; and an acceptable excipient. Also disclosed are compositions comprising a targeted corrole nanoparticle; and an acceptable carrier. Further, disclosed herein are methods of imaging a condition in a subject, comprising providing a composition comprising a targeted corrole nanoparticle; administering an effective amount of the targeted corrole nanoparticle to the subject; and imaging the condition in the subject. In addition, disclosed herein are methods of treating cancer in a subject, comprising providing a composition comprising a targeted corrole nanoparticle; and administering a therapeutically effective dosage of the targeted corrole nanoparticle to the subject.Type: ApplicationFiled: June 15, 2017Publication date: October 5, 2017Inventor: Lali K. MEDINA-KAUWE
-
Patent number: 9757386Abstract: Disclosed herein are compositions comprising a targeted corrole nanoparticle; and an acceptable excipient. Also disclosed are compositions comprising a targeted corrole nanoparticle; and an acceptable carrier. Further, disclosed herein are methods of imaging a condition in a subject, comprising providing a composition comprising a targeted corrole nanoparticle; administering an effective amount of the targeted corrole nanoparticle to the subject; and imaging the condition in the subject. In addition, disclosed herein are methods of treating cancer in a subject, comprising providing a composition comprising a targeted corrole nanoparticle; and administering a therapeutically effective dosage of the targeted corrole nanoparticle to the subject.Type: GrantFiled: May 8, 2014Date of Patent: September 12, 2017Assignee: CEDARS-SINAI MEDICAL CENTERInventor: Lali K. Medina-Kauwe